Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD‐1) or programmed cell death ligand 1 (PD‐L1) in combination with chemotherapy represent the standard of care for patients with driver‐gene negative and advanced non‐small cell lung cancer (NSCLC). The gene discussed is CD274; the disease is lung cancer.